WO1998004728A1 - Recombinant pox virus for immunization against tumor-associated antigens - Google Patents
Recombinant pox virus for immunization against tumor-associated antigens Download PDFInfo
- Publication number
- WO1998004728A1 WO1998004728A1 PCT/US1997/012546 US9712546W WO9804728A1 WO 1998004728 A1 WO1998004728 A1 WO 1998004728A1 US 9712546 W US9712546 W US 9712546W WO 9804728 A1 WO9804728 A1 WO 9804728A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- recombinant
- virus
- gene
- pox virus
- tumor
- Prior art date
Links
- 241000700605 Viruses Species 0.000 title claims abstract description 88
- 206010028980 Neoplasm Diseases 0.000 title claims abstract description 42
- 239000000427 antigen Substances 0.000 title claims abstract description 39
- 102000036639 antigens Human genes 0.000 title claims abstract description 39
- 108091007433 antigens Proteins 0.000 title claims abstract description 39
- 230000003053 immunization Effects 0.000 title description 8
- 238000002649 immunization Methods 0.000 title description 8
- 108010002350 Interleukin-2 Proteins 0.000 claims description 22
- 238000000034 method Methods 0.000 claims description 18
- 108010010995 MART-1 Antigen Proteins 0.000 claims description 16
- 102000016200 MART-1 Antigen Human genes 0.000 claims description 11
- NEHKZPHIKKEMAZ-ZFVKSOIMSA-N (2s)-2-[[(2s,3r)-2-[[(2s)-2-[[(2s,3s)-2-[[2-[[(2s,3s)-2-[[2-[[(2s)-2-[[(2s)-2-azaniumylpropanoyl]amino]propanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]acetyl]amino]-3-methylpentanoyl]amino]-4-methylpentanoyl]amino]-3-hydroxybutanoyl]amino]-3-methylb Chemical compound C[C@H](N)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](C(C)C)C(O)=O NEHKZPHIKKEMAZ-ZFVKSOIMSA-N 0.000 claims 1
- 230000028993 immune response Effects 0.000 abstract description 8
- 230000000763 evoking effect Effects 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 description 65
- 239000013612 plasmid Substances 0.000 description 31
- 210000004027 cell Anatomy 0.000 description 30
- 108020004414 DNA Proteins 0.000 description 25
- 206010046865 Vaccinia virus infection Diseases 0.000 description 25
- 208000007089 vaccinia Diseases 0.000 description 25
- 239000013598 vector Substances 0.000 description 22
- 208000000666 Fowlpox Diseases 0.000 description 19
- 102000000588 Interleukin-2 Human genes 0.000 description 16
- 230000003612 virological effect Effects 0.000 description 15
- 241000700662 Fowlpox virus Species 0.000 description 14
- 238000001727 in vivo Methods 0.000 description 13
- 239000012634 fragment Substances 0.000 description 12
- 238000003780 insertion Methods 0.000 description 12
- 230000037431 insertion Effects 0.000 description 12
- 102000004169 proteins and genes Human genes 0.000 description 12
- 238000010276 construction Methods 0.000 description 11
- 230000006798 recombination Effects 0.000 description 11
- 238000005215 recombination Methods 0.000 description 11
- 229960005486 vaccine Drugs 0.000 description 11
- 108010022366 Carcinoembryonic Antigen Proteins 0.000 description 10
- 102100025475 Carcinoembryonic antigen-related cell adhesion molecule 5 Human genes 0.000 description 10
- 241000700618 Vaccinia virus Species 0.000 description 10
- 201000011510 cancer Diseases 0.000 description 10
- 230000014509 gene expression Effects 0.000 description 10
- 241000588724 Escherichia coli Species 0.000 description 9
- 241000699670 Mus sp. Species 0.000 description 9
- 101150066555 lacZ gene Proteins 0.000 description 9
- 108020004440 Thymidine kinase Proteins 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 102000006601 Thymidine Kinase Human genes 0.000 description 7
- 239000013600 plasmid vector Substances 0.000 description 7
- 230000010076 replication Effects 0.000 description 7
- 230000002103 transcriptional effect Effects 0.000 description 7
- 239000002671 adjuvant Substances 0.000 description 6
- 238000003556 assay Methods 0.000 description 6
- 210000001151 cytotoxic T lymphocyte Anatomy 0.000 description 6
- 230000006801 homologous recombination Effects 0.000 description 6
- 238000002744 homologous recombination Methods 0.000 description 6
- 239000003550 marker Substances 0.000 description 6
- 239000002609 medium Substances 0.000 description 6
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 6
- 108090000765 processed proteins & peptides Proteins 0.000 description 6
- 210000004881 tumor cell Anatomy 0.000 description 6
- 239000013603 viral vector Substances 0.000 description 6
- 102000004190 Enzymes Human genes 0.000 description 5
- 108090000790 Enzymes Proteins 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- 208000015181 infectious disease Diseases 0.000 description 5
- 201000001441 melanoma Diseases 0.000 description 5
- 241000700663 Avipoxvirus Species 0.000 description 4
- 102000004127 Cytokines Human genes 0.000 description 4
- 108090000695 Cytokines Proteins 0.000 description 4
- 102000003886 Glycoproteins Human genes 0.000 description 4
- 108090000288 Glycoproteins Proteins 0.000 description 4
- 241000700629 Orthopoxvirus Species 0.000 description 4
- 102000007066 Prostate-Specific Antigen Human genes 0.000 description 4
- 108010072866 Prostate-Specific Antigen Proteins 0.000 description 4
- 210000001744 T-lymphocyte Anatomy 0.000 description 4
- 102000005936 beta-Galactosidase Human genes 0.000 description 4
- 108010005774 beta-Galactosidase Proteins 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 230000002163 immunogen Effects 0.000 description 4
- 238000001802 infusion Methods 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- LINMATFDVHBYOS-MBJXGIAVSA-N (2s,3r,4s,5r,6r)-2-[(5-bromo-1h-indol-3-yl)oxy]-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C=C12 LINMATFDVHBYOS-MBJXGIAVSA-N 0.000 description 3
- 241000271566 Aves Species 0.000 description 3
- 102000053602 DNA Human genes 0.000 description 3
- 241001529936 Murinae Species 0.000 description 3
- 230000024932 T cell mediated immunity Effects 0.000 description 3
- 241000700647 Variola virus Species 0.000 description 3
- 108020005202 Viral DNA Proteins 0.000 description 3
- 210000000612 antigen-presenting cell Anatomy 0.000 description 3
- 239000003593 chromogenic compound Substances 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 210000000987 immune system Anatomy 0.000 description 3
- 239000002955 immunomodulating agent Substances 0.000 description 3
- 229940121354 immunomodulator Drugs 0.000 description 3
- 238000009169 immunotherapy Methods 0.000 description 3
- 238000002955 isolation Methods 0.000 description 3
- 230000004044 response Effects 0.000 description 3
- 230000035899 viability Effects 0.000 description 3
- 241000700664 Capripoxvirus Species 0.000 description 2
- 201000009030 Carcinoma Diseases 0.000 description 2
- 101001002657 Homo sapiens Interleukin-2 Proteins 0.000 description 2
- 108010002352 Interleukin-1 Proteins 0.000 description 2
- 108010008038 Synthetic Vaccines Proteins 0.000 description 2
- AVKUERGKIZMTKX-NJBDSQKTSA-N ampicillin Chemical compound C1([C@@H](N)C(=O)N[C@H]2[C@H]3SC([C@@H](N3C2=O)C(O)=O)(C)C)=CC=CC=C1 AVKUERGKIZMTKX-NJBDSQKTSA-N 0.000 description 2
- 229960000723 ampicillin Drugs 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 230000006023 anti-tumor response Effects 0.000 description 2
- 238000013459 approach Methods 0.000 description 2
- 230000001580 bacterial effect Effects 0.000 description 2
- 230000001413 cellular effect Effects 0.000 description 2
- 210000003837 chick embryo Anatomy 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 230000029087 digestion Effects 0.000 description 2
- -1 e.g. Proteins 0.000 description 2
- 238000003018 immunoassay Methods 0.000 description 2
- 230000001024 immunotherapeutic effect Effects 0.000 description 2
- 238000011065 in-situ storage Methods 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 231100000518 lethal Toxicity 0.000 description 2
- 230000001665 lethal effect Effects 0.000 description 2
- 210000004698 lymphocyte Anatomy 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 102000004196 processed proteins & peptides Human genes 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003156 radioimmunoprecipitation Methods 0.000 description 2
- 229940124551 recombinant vaccine Drugs 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 108091008146 restriction endonucleases Proteins 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 238000011282 treatment Methods 0.000 description 2
- 210000003171 tumor-infiltrating lymphocyte Anatomy 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 230000001018 virulence Effects 0.000 description 2
- OPIFSICVWOWJMJ-AEOCFKNESA-N 5-bromo-4-chloro-3-indolyl beta-D-galactoside Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1OC1=CNC2=CC=C(Br)C(Cl)=C12 OPIFSICVWOWJMJ-AEOCFKNESA-N 0.000 description 1
- 208000030507 AIDS Diseases 0.000 description 1
- 208000010507 Adenocarcinoma of Lung Diseases 0.000 description 1
- 101150045267 CEA gene Proteins 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 241000272201 Columbiformes Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- YVGGHNCTFXOJCH-UHFFFAOYSA-N DDT Chemical compound C1=CC(Cl)=CC=C1C(C(Cl)(Cl)Cl)C1=CC=C(Cl)C=C1 YVGGHNCTFXOJCH-UHFFFAOYSA-N 0.000 description 1
- 108020003215 DNA Probes Proteins 0.000 description 1
- 239000003298 DNA probe Substances 0.000 description 1
- 208000006586 Ectromelia Diseases 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- 108700028146 Genetic Enhancer Elements Proteins 0.000 description 1
- 102000025850 HLA-A2 Antigen Human genes 0.000 description 1
- 108010074032 HLA-A2 Antigen Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 101100321817 Human parvovirus B19 (strain HV) 7.5K gene Proteins 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 241000700563 Leporipoxvirus Species 0.000 description 1
- 206010024503 Limb reduction defect Diseases 0.000 description 1
- 241000282560 Macaca mulatta Species 0.000 description 1
- 241000712079 Measles morbillivirus Species 0.000 description 1
- 102000007557 Melanoma-Specific Antigens Human genes 0.000 description 1
- 108010071463 Melanoma-Specific Antigens Proteins 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 241000700627 Monkeypox virus Species 0.000 description 1
- 108010008707 Mucin-1 Proteins 0.000 description 1
- 102100034256 Mucin-1 Human genes 0.000 description 1
- 108010063954 Mucins Proteins 0.000 description 1
- 108700020796 Oncogene Proteins 0.000 description 1
- 102000043276 Oncogene Human genes 0.000 description 1
- 229930182555 Penicillin Natural products 0.000 description 1
- JGSARLDLIJGVTE-MBNYWOFBSA-N Penicillin G Chemical compound N([C@H]1[C@H]2SC([C@@H](N2C1=O)C(O)=O)(C)C)C(=O)CC1=CC=CC=C1 JGSARLDLIJGVTE-MBNYWOFBSA-N 0.000 description 1
- 241000700625 Poxviridae Species 0.000 description 1
- 241000700564 Rabbit fibroma virus Species 0.000 description 1
- 206010037742 Rabies Diseases 0.000 description 1
- 241000711798 Rabies lyssavirus Species 0.000 description 1
- 241000700638 Raccoonpox virus Species 0.000 description 1
- 101000702488 Rattus norvegicus High affinity cationic amino acid transporter 1 Proteins 0.000 description 1
- 231100000645 Reed–Muench method Toxicity 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 241000287219 Serinus canaria Species 0.000 description 1
- 238000002105 Southern blotting Methods 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 241000700568 Suipoxvirus Species 0.000 description 1
- 241000700565 Swinepox virus Species 0.000 description 1
- 230000005867 T cell response Effects 0.000 description 1
- 101150003725 TK gene Proteins 0.000 description 1
- 206010053613 Type IV hypersensitivity reaction Diseases 0.000 description 1
- 108010059722 Viral Fusion Proteins Proteins 0.000 description 1
- 241001536558 Yaba monkey tumor virus Species 0.000 description 1
- DVKFVGVMPLXLKC-PUGXJXRHSA-N [(2s,3r,4s,5s,6r)-2-[(2s,3s,4s,5r)-3,4-dihydroxy-2,5-bis(hydroxymethyl)oxolan-2-yl]-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] dihydrogen phosphate Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@]1(CO)[C@@]1(OP(O)(O)=O)[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 DVKFVGVMPLXLKC-PUGXJXRHSA-N 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000002494 anti-cea effect Effects 0.000 description 1
- 230000000259 anti-tumor effect Effects 0.000 description 1
- 238000011398 antitumor immunotherapy Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 239000007900 aqueous suspension Substances 0.000 description 1
- 230000003416 augmentation Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 201000008275 breast carcinoma Diseases 0.000 description 1
- 238000002619 cancer immunotherapy Methods 0.000 description 1
- 229940022399 cancer vaccine Drugs 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000013592 cell lysate Substances 0.000 description 1
- 239000013553 cell monolayer Substances 0.000 description 1
- 238000002659 cell therapy Methods 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000010367 cloning Methods 0.000 description 1
- 230000000295 complement effect Effects 0.000 description 1
- 239000002299 complementary DNA Substances 0.000 description 1
- 230000000139 costimulatory effect Effects 0.000 description 1
- 210000000805 cytoplasm Anatomy 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 230000002500 effect on skin Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000008029 eradication Effects 0.000 description 1
- 210000003527 eukaryotic cell Anatomy 0.000 description 1
- 238000010195 expression analysis Methods 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 210000002950 fibroblast Anatomy 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 210000001035 gastrointestinal tract Anatomy 0.000 description 1
- 229930195712 glutamate Natural products 0.000 description 1
- ZDXPYRJPNDTMRX-UHFFFAOYSA-N glutamine Natural products OC(=O)C(N)CCC(N)=O ZDXPYRJPNDTMRX-UHFFFAOYSA-N 0.000 description 1
- 210000003714 granulocyte Anatomy 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 238000009396 hybridization Methods 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 230000000984 immunochemical effect Effects 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000007918 intramuscular administration Methods 0.000 description 1
- 238000001990 intravenous administration Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 239000003446 ligand Substances 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 230000001589 lymphoproliferative effect Effects 0.000 description 1
- 210000002752 melanocyte Anatomy 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 208000005871 monkeypox Diseases 0.000 description 1
- UXOUKMQIEVGVLY-UHFFFAOYSA-N morin Natural products OC1=CC(O)=CC(C2=C(C(=O)C3=C(O)C=C(O)C=C3O2)O)=C1 UXOUKMQIEVGVLY-UHFFFAOYSA-N 0.000 description 1
- 210000005170 neoplastic cell Anatomy 0.000 description 1
- 231100000956 nontoxicity Toxicity 0.000 description 1
- 231100000590 oncogenic Toxicity 0.000 description 1
- 230000002246 oncogenic effect Effects 0.000 description 1
- 238000007911 parenteral administration Methods 0.000 description 1
- 229940049954 penicillin Drugs 0.000 description 1
- 239000002504 physiological saline solution Substances 0.000 description 1
- 229920001184 polypeptide Polymers 0.000 description 1
- 238000012809 post-inoculation Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000000644 propagated effect Effects 0.000 description 1
- 238000011536 re-plating Methods 0.000 description 1
- 210000001525 retina Anatomy 0.000 description 1
- 239000000523 sample Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 229940083538 smallpox vaccine Drugs 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 238000007920 subcutaneous administration Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 238000004448 titration Methods 0.000 description 1
- 238000013518 transcription Methods 0.000 description 1
- 230000035897 transcription Effects 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 230000005951 type IV hypersensitivity Effects 0.000 description 1
- 208000027930 type IV hypersensitivity disease Diseases 0.000 description 1
- 241001430294 unidentified retrovirus Species 0.000 description 1
- 238000011144 upstream manufacturing Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001136—Cytokines
- A61K39/00114—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001191—Melan-A/MART
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00119—Melanoma antigens
- A61K39/001192—Glycoprotein 100 [Gp100]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2799/00—Uses of viruses
- C12N2799/02—Uses of viruses as vector
- C12N2799/021—Uses of viruses as vector for the expression of a heterologous nucleic acid
- C12N2799/023—Uses of viruses as vector for the expression of a heterologous nucleic acid where the vector is derived from a poxvirus
Definitions
- TAAs tumor-associated antigens
- These antigens which include viral tumor antigens, cellular oncogene proteins, and tumor-associated differentiation antigens, can serve as targets for the host immune system and elicit responses which result in tumor destruction.
- This immune response is mediated primarily by lymphocytes; T cells in general and class I MHC-restricted cytotoxic T lymphocytes in particular play a central role in tumor rejection.
- MART-1 Melanoma Antigen Recognized by T cells - 1
- gp100 Two such antigens have been designated MART-1 (Melanoma Antigen Recognized by T cells - 1 ) and gp100. Proc. Natl. Acad. Sci. U.S.A. 91 :351 5-3519. MART-1 and gp 100 appear to be expressed in virtually all fresh and cultured melanomas. With the exception of melanocyte and retina, no normal tissues express the antigens. The antigens may be responsible for mediating tumor regression in patients with advanced melanoma, since the tumor-infiltrating lymphocytes (TIL) used to identify MART-1 and gp100 were capable of effecting tumor regression in vivo. Thus, immunization of melanoma patients with MART-1 or gp100 may boost their cellular immune responses against their cancers.
- TIL tumor-infiltrating lymphocytes
- CEA carcinoembryonic antigen
- Pox viruses of the family Poxviridae (pox viruses) are useful as vectors for the delivery of foreign genes and gene products in many clinical and research settings.
- Pox viruses of the genus Orthopoxvirus, particularly vaccinia are used for several reasons. Among these are: (a) its wide use in humans in the eradication of smallpox; (b) its ability to infect a wide range of cells, including professional antigen presenting cells, and express the inserted gene product (i.e. foreign gene product) in a manner that has the potential to be processed in the context of class I and/or class II MHC molecules; and (c) use as a recombinant vaccine in the treatment of certain tumors (Kantor, J. et al. ( 1 992)).
- Fowlpox vii us is a member of the avipox virus family. Productive FPV infection is restricted in vivo to cells derived from avian species; however, FPV-mediated gene expression does occur in infected non-avian cells. Taylor, J. et al., (1 988) Vaccine 6:497-503.
- Fowlpox virus based recombinant vaccines are described in: Technological Advances in Vaccine Development (Alan R. Liss, Inc.) pp. 321 -334. Furthermore, in vivo FPV-mediated gene expression in several mammalian species has been demonstrated. Six non-avian species immunized with live recombinant fowlpox virus expressing the rabies glycoprotein developed antibodies against this glycoprotein. Immunization with this recombinant FPV elicited antibodies against this glycoprotein. Immunization with this recombinant FPV partially protected mice, cats, and dogs against a rabies virus challenge.
- the present invention relates to recombinant pox viruses capable of expressing cell-encoded tumor associated antigens and/or immunomodulators.
- Recombinant pox virus capable of expressing a cell-encoded tumor-associated antigen are produced by integrating into the pox virus genome sequences encoding the antigen or immunogenic portions thereof.
- Tumor associated antigens include molecules expressed by tumor cells (e.g. carcinoembryonic antigen, prostate-specific antigen
- Immunomodulators include interleukin 2, B7.1 and B7.2.
- Particularly preferred recombinant pox viruses include rV-MART- 1 (vaccinia, MART-1 ), rF-MART-1 (fowlpox, MART-1 ), rV-gp100
- Figure 1 is a plasmid map of pT2055, the donor plasmid used in the construction of rF-MART-1 .
- Figure 2 is a plasmid map of pT2054, the donor plasmid used in the construction of rV-MART-1 .
- Figure 3 is a plasmid map of pT2058, the donor plasmid used in the construction of rV-gp100.
- Figure 4 is a plasmid map of pT2057, the donor plasmid used in the construction of rF-gp100.
- Figure 5 is a plasmid map of pT4048, the donor plasmid used in the construction of rV-gp100/IL-2.
- Figure 6 is a plasmid map of pT2077, the donor plasmid used in the construction of rF-gp100/IL-2.
- Pox viruses serve as effective vectors for inducing immunity against tumor-associated antigens.
- tumor-associated antigens are cell surface molecules. These are positioned for recognition by elements of the immune systems and thus are excellent targets for immunotherapy.
- Tumor-associated antigens are expressed by certain tumor cells and provide effective targets for immunotherapy. Some examples are carcinoembryonic antigen (CEA), prostate-specific antigen (PSA), and melanoma specific antigens.
- Immunomodulators can regulate immune responses, increasing the likelihood of a sufficient cellular immune response occurring, (e.g. IL-2) or can provide cellular ligand necessary for stimulating a CTL response (e.g. B7.1 or B7.2)
- Patent No. 5,093,258 the disclosure of which is incorporated herein by reference.
- Other techniques include using a unique restriction endonuclease site that is naturally present or artificially inserted in the parental viral vector to insert the heterologous DNA. See, U.S. Patent No. 5,445,953, incorporated herein by reference.
- Pox viruses useful in practicing the present invention include orthopox, suipox, avipox and capripoxvirus.
- Orthopox virus include vaccinia, ectromelia and raccoon pox.
- the preferred orthopox is vaccinia. More preferred is a sub-clone of vaccinia having decreased virulence relative to a standard vaccine strain of vaccinia.
- Avipox viruses include fowlpox, canary pox and pigeon pox.
- the preferred avipox is fowlpox.
- a preferred suipox is swinepox.
- the DNA gene sequence to be inserted into the virus can be placed into a donor plasmid, e.g., an E. coli plasmid construct.
- a donor plasmid e.g., an E. coli plasmid construct.
- the DNA gene sequence to be inserted is ligated to a promoter.
- the promoter-gene linkage is positioned in the plasmid construct so that the promoter-gene linkage is flanked on both ends by DNA homologous to a DNA sequence flanking a region of pox DNA which is the desired insertion region.
- a pox promoter is used with a parental pox viral vector.
- the resulting plasmid construct is then amplified by growth within E. coli bacteria and isolated.
- the plasmid also contains an origin of replication such as the E. coli origin of replication, and a marker such as an antibiotic resistance gene for selection and propagation in E. coli.
- the isolated plasmid containing the DNA gene sequence to be inserted is transfected into a cell culture, e.g., chick embryo fibroblasts, along with the parental virus, e.g., poxvirus.
- a cell culture e.g., chick embryo fibroblasts
- the parental virus e.g., poxvirus.
- Recombination between homologous pox DNA in the plasmid and the viral genome respectively results in a recombinant poxvirus modified by the presence of the promoter-gene construct in its genome, at a site which does not affect virus viability.
- the gene is inserted into a region (insertion region), in the virus which does not affect virus viability of the resultant recombinant virus.
- a region insertion region
- the skilled artisan can readily identify such regions in a virus by, for example, randomly testing segments of virus DNA for regions that allow recombinant formation without seriously affecting virus viability of the recombinant.
- One region that can readily be used and is present in many viruses is the thymidine kinase (TK) gene.
- TK thymidine kinase
- the TK gene has been found in all pox virus genomes examined [leporipoxvirus: Upton, et al., J. Virology, 60:920 (1 986)
- insertion regions include, for example, Hindlll M.
- insertion regions include, for example, BamHI J [Jenkins, et al., AIDS Research and Human Retroviruses 7:991 -998 (1 991 )] the £coRI-/V//7_/lll fragment, BamYW fragment, EcoR ⁇ /-Hind ⁇ fragment, BamH ⁇ fragment and the Hind ⁇ fragment set forth in EPO Application No. 0 308 220 A1 .
- BamHI J Jenkins, et al., AIDS Research and Human Retroviruses 7:991 -998 (1 991 )
- the £coRI-/V//7_/lll fragment BamYW fragment
- EcoR ⁇ /-Hind ⁇ fragment BamH ⁇ fragment
- Hind ⁇ fragment set forth in EPO Application No. 0 308 220 A1 .
- preferred insertion sites include the thymidine kinase gene region.
- the promoter must be placed so that it is located upstream from the gene to be expressed. Promoters are well known in the art and can readily be selected depending on the host and the cell type you wish to target. For example in poxviruses, pox viral promoters should be used, such as the vaccinia 7.5K, or 40K or fowlpox C1 . Artificial constructs containing appropriate pox sequences can also be used. Enhancer elements can also be used in combination to increase the level of expression. Furthermore, the use of inducible promoters, which are also well known in the art, are preferred in some embodiments.
- Live recombinant viruses expressing an immunogenic cell encoded tumor associated antigen can be used to induce an immune response against tumor cells which express the protein.
- These recombinant viruses may be administered by intradermal scarification, as was conventionally done for small pox vaccination, or by other routes appropriate to the recombinant virus used. These may include among others, intramuscular, subcutaneous, and intravenous routes. Vaccination of a host organism with live recombinant vaccinia virus is followed by replication of the virus within the host.
- the recombinant vectors will typically be injected in a sterile aqueous or non-aqueous solution, suspension or emulsion in association with a pharmaceutically- acceptable carrier such as physiological saline.
- a specific immune response to a tumor associated antigen can be generated by administering between about 1 0 5 -1 0 9 pfu of the recombinant pox virus, constructed as discussed above to a host, more preferably one uses _>.1 0 7 pfu.
- the preferred host is a human.
- At least one interval thereafter, which is preferably one to three months later, the immune response is boosted by administering additional antigen to the host. More preferably there is at least a second "boost" preferably at least one to three months after the first boost, more preferably 6-12 months after the first boost.
- the antigen for boosting may be administered using the same pox virus vector.
- the boosting antigen may be administered as a whole protein, an immunogenic peptide fraction of the protein, or DNA encoding the protein or peptide.
- the boosting antigen may preferably be administered using a second pox virus vector from a different pox genus, or may be administered directly, for example, purified protein plus an adjuvant or in a liposome formation.
- Cytokines e.g., IL-2, IL-6, IL-1 2, IL-1 5, or co-stimulatory molecules, e.g., B7.1 , B7.2, may be used as biologic adjuvants.
- the cytokines can be administered systemically to the host, either cytokines or costimulatory molecules can be co-administered via insertion of the genes encoding the molecules into the recombinant pox vector or a second recombinant poxvirus which is admixed with the recombinant poxvirus expressing the TAA.
- Adjuvants include, for example, RIBI Detox (Ribi
- Cytotoxic T-cells specific for a tumor specific antigen can be established from peripheral blood mononuclear cells (PBMC) obtained from a host immunized as discussed above.
- PBMC peripheral blood mononuclear cells
- PBMC can be separated by using Lymphocyte Separation Medium gradient (Organon Teknika, Durham, NC, USA) as previously described [Boyum, et al., Scand J. Clin Lab Invest 21 : 77-80 (1 968)].
- Washed PBMC are resuspended in a complete medium, for example, RPMI 1 640 (GIBCO) supplemented with 10% pool human AB serum (Pel-Freeze Clinical System, Brown Dear, Wl, USA), 2mM glutamine, 1 00 U/ml penicillin and 100 ⁇ g/ml of streptomycin (GIBCO) .
- PBMC at a concentration of about 2 x 1 0 5 cells in complete medium in a volume of, for example, 100 ⁇ are added into each well of a 96-well flat-bottom assay plate (Costar, Cambridge, MA, USA).
- the antigen or peptides are added into the cultures in a final concentration of about 50 ⁇ glmi and incubated at 37°C in a humidified atmosphere containing 5% CO 2 for 5 days. After removal of peptide containing media, the cultures are provided with fresh human IL-2 (10U/ml) after 5 days and replenished with IL-2 containing medium every 3 days. Primary cultures are restimulated with the same peptide (50 ⁇ g/ml) on day 1 6. 5 x 10 5 irradiated (4,000 rad) autologous PBMC are added in a volume of about 50 ⁇ complete medium as antigen-presenting cells (APC) . About five days later, the cultures are provided with human IL-2 containing medium as described previously. Cells are restimulated for 5 days at intervals of 1 6 days.
- the cytotoxic T-cell can be cultured to amplify its number and then injected back into the host by a variety of means. Generally, between 1 x 10 5 and 2 x 10" cytotoxic T-cells per infusion are administered in, for example, one to three infusions of 200 to 250 ml each over a period of 30 to 60 minutes. After the completion of the infusions, the patient may be treated with recombinant interleukin-2 with a dose of 720,000 IU per kilogram of body weight intravenously every eight hours; some doses can be omitted depending on the patient's tolerance for the drug.
- additional antigen or fragments containing T-cell eliciting epitope(s) may be administered to the patient to further expand the T-cell number.
- the antigen or epitope may be formulated with an adjuvant and/or may be in a liposomal formulation.
- the cytotoxic T-cells can also be modified by introduction of a viral vector containing a DNA encoding TNF and reintroduced into a host in an effort to enhance the anti-tumor activity of the cells.
- Other cytokines can also be used.
- pox viruses have been developed as live viral vectors for the expression of heterologous proteins (Cepko et al., Cell 37: 1 053-1062 (1 984); Morin et al., Proc. Natl. Acad. Sci. USA 84:4626-4630 ( 1 987); Lowe et al., Proc. Natl. Acad. Sci. USA, 84:3896-3900 (1987); Panicali & Paoletti, Proc. Natl. Acad. Sci. USA,
- the parental fowlpox virus is a plaque purified isolate of the POXVAC-TC vaccine strain of fowlpox virus (Schering Corp.).
- the parental vaccinia virus (clone B-3-1 ) is a plaque-purified isolate of the Wyeth strain that was received from Flow Laboratories.
- the Wyeth strain of vaccinia was passaged in the fetal rhesus lung line FRhL (ATCC Accession No. CL1 60) as follows: Pass 1 : Plaque "B” was picked at 1 0- 5 3 dilution Pass 2: Plaque "B-3” was picked at 1 0- 1 6 dilution Pass 3: Plaque "B-3-1 " was picked at 10- 1 6 dilution Pass 4-7: Plaque B-3-1 was serially passaged using serum-free medium with sucrose phosphate glutamate (SPG) to prepare a small seed pool at the 7th passage level.
- SPG sucrose phosphate glutamate
- the virulence of this plaque isolate of the Wyeth vaccinia strain was assessed by determining the infections dose of the virus lethal to
- mice 50% (LD 50 ) of weaning mice infected intracranially.
- LD 50 50% (LD 50 ) of weaning mice infected intracranially.
- Two to three week old immunocompetent mice were inoculated with various doses of virus (7 mice/dose); the LD 50 was determined on mice succubing between 2 and 12 days post-inoculation by calculating the 50% endpoint using the Reed-Muench method (20). These values were compared to those obtained using a virus stock prepared by expanding virus directly from a vial of the CDC Smallpox Vaccine (Table 1 ).
- Genes that code for desired carcinoma associated antigens are inserted into the genome of a pox virus in such a manner as to allow them to be expressed by that virus along with the expression of the normal complement of parent virus proteins. This can be accomplished by first constructing a DNA donor vector for in vivo recombination with a pox virus.
- the DNA donor vector contains the following elements:
- a prokaryotic origin of replication so that the vector may be amplified in a prokaryotic host
- a gene encoding a marker which allows selection of prokaryotic host cells that contain the vector e.g., a gene encoding antibiotic resistance
- at least one gene encoding a desired protein located adjacent to a transcriptional promoter capable of directing the expression of the gene e.g., DNA sequences homologous to the region of the parent virus genome where the foreign gene(s) will be inserted, flanking the construct of element (iii).
- donor plasmids for the introduction of multiple foreign genes into pox virus are described in W091 /1 9803, the techniques of which are incorporated herein by reference.
- all DNA fragments for construction of the donor vector including fragments containing transcriptional promoters and fragments containing sequences homologous to the region of the parent virus genome into which foreign genes are to be inserted, can be obtained from genomic DNA or cloned DNA fragments.
- the donor plasmids can be mono-,di-, or multivalent (i.e., can contain one or more inserted foreign gene sequences) .
- the donor vector preferably contains an additional gene which encodes a marker which will allow identification of recombinant viruses containing inserted foreign DNA.
- a marker which will allow identification of recombinant viruses containing inserted foreign DNA.
- Several types of marker genes can be used to permit the identification and isolation of recombinant viruses.
- genes that encode antibiotic or chemical resistance include genes that encode antibiotic or chemical resistance (e.g., see Spyropoulos et al., J. Virol. , 62: 1046 (1988); Falkner and Moss., J. Virol. , 62: 1 849 (1 988); Franke et al., Mol. Cell. Bio/. , 5: 191 8 ( 1 985), as well as genes such as the E. coli lacZ gene, that permit identification of recombinant viral plaques by coiorimetric assay
- host cells for in vivo recombination are generally eukaryotic cells that can be infected by the virus and transfected by the plasmid vector.
- Examples of such cells suitable for use with a pox virus are chick embryo dermal (CED) cells, HuTK1 3 (human) ceils, and CV-1 and BSC-40 (both monkey kidney) cells. Infection of cells with pox virus and transfection of these cells with plasmid vectors is accomplished by techniques standard in the art (Panicali and Paoletti, U.S. Patent No. 4,603, 1 1 2,
- recombinant viral progeny can be identified by one of several techniques. For example, if the DNA donor vector is designed to insert foreign genes into the parent virus thymidine kinase (TK) gene, viruses containing integrated DNA will be TK " and can be selected on this basis (Mackett et al., Proc. Natl. Acad. Sci. USA, 79:741 5 ( 1 982)) . Alternatively, co-integration of a gene encoding a marker or indicator gene with the foreign gene(s) of interest, as described above, can be used to identify recombinant progeny.
- One preferred indicator gene is the E. coli lacZ gene: recombinant viruses expressing ⁇ -galactosidase can be selected using a chromogenic substrate for the enzyme (Panicali et al., Gene, 47: 1 93 (1986)).
- recombinant viral progeny can be identified by one of several techniques.
- the presence of integrated foreign DNA can be detected by hybridization with a labeled DNA probe specific for the inserted DNA.
- Preferred techniques for selection are based upon co-integration of a gene encoding a marker or indicator gene along with the gene of interest, as described above.
- a preferred indicator gene is the E. coli lacZ gene which encodes the enzyme ⁇ -galactosidase.
- Selection of recombinant virus expressing ⁇ - galactosidase can be done by employing a chromogenic substrate for the enzyme.
- recombinant viruses are detected as blue plaques in the presence of the substrate 5-bromo-4-chloro-3-indolyl- ⁇ - D-galactoside or other halogenated-indolyl- ⁇ -D-galactoside (e.g., BluoGalTM).
- black plaque assay an in situ enzyme immunoassay performed on viral plaques
- Western blot analysis a variety of methods can be used to assay the expression of the polypeptide encoded by the inserted gene.
- RIPA radioimmunoprecipitation
- EIA enzyme immunoassay
- This vector contains the following elements: ( 1 ) a prokaryotic origin of replication to allow amplification of the vector in a bacterial host; (2) the gene encoding resistance to the antibiotic ampicillin, to permit selection of prokaryotic host cells that contain the plasmid; (3) DNA sequences homologous to the Hindlll M region of the vaccinia genome, which direct insertion of foreign sequences into this region via homologous recombination; (4) a chimeric gene comprising the vaccinia 40K transcriptional promotor linked to the gpl OO gene; (5) a second chimeric gene comprising the fowlpox C1 transcriptional promoter linked to the E. coli lacZ gene.
- a plaque-purified isolate from the Wyeth (New York City Board of Health) strain of vaccinia was used as the parental virus in the construction of the recombinant vaccinia virus, rV-gp100.
- the generation of recombinant vaccinia virus was accomplished via homologous recombination between vaccinia sequences in the Wyeth vaccinia genome and the corresponding sequences in pT2058 in vaccinia-infected RK 13 cells (CCL 37, ATCC) transfected with pT2058.
- Recombinant virus was identified using a chromogenic assay, performed on viral plaques in situ, that detects expression of the lacZ gene product in the presence of halogenated indolyl-beta-D-galactoside (Bluo-gal), as described previously (Panacali, et al., 1986) .
- Appropriate blue recombinant viruses were purified by four rounds of plaque- purification.
- Virus stocks were prepared by clarifying infected RK 13 cell lysates followed by centrifugation through a 36% sucrose cushion.
- the generation of recombinant fowlpox viruses is accomplished via homologous recombination in vivo between fowlpox DNA and a plasmid vector that carries the heterologous sequences to be inserted.
- the plasmid vectors contain one or more chimeric genes, each comprising a poxvirus promoter linked to a protein coding sequence, flanked by viral sequences from a non-essential region of the fowlpox virus genome.
- the plasmid is transfected into cells infected with the parental fowlpox virus, and recombination between fowlpox sequences on the plasmid and the corresponding DNA in the viral genome results in the insertion into the viral genome of the chimeric genes on the plasmid.
- the plasmid vector (pT2055) used for insertion of the MART-1 gene into the parental fowlpox virus genome by in vivo recombination is illustrated in Figure 1 .
- This vector contains the following elements: (1 ) a prokaryotic origin of replication to allow amplification of the vector in a bacterial host; (2) the gene encoding resistance to the antibiotic ampicillin, to permit selection of prokaryotic host cells that contain the plasmid; (3) DNA sequences homologous to the BamHIJ region of the fowlpox genome, which direct insertion of foreign sequences into this region via homologous recombination; (4) a chimeric gene comprising the vaccinia 40K transcriptional promotor linked to the MART-1 gene; (5) a second chimeric gene comprising the fowlpox C1 transcriptional promoter linked to the E. coli lacZ gene.
- MART-1 The gene encoding MART-1 was isolated at the National Cancer Institute from a cDNA library derived from RNA from the HLA-A2 + melanoma cell line 501 mel. Kawakami, Y., et al., ( 1994) Proc. Natl. Acad. Sci. U.S.A. 91 :3515-351 9.
- a plaque-purified isolate from the POXVAC-TC vaccine strain of fowlpox virus was used as the parental virus for this recombinant vaccine.
- In vivo recombination between the plasmid vector and the viral DNA resulted in the formation of a recombinant virus in which the MART-1 gene, under the transcriptional direction of the vaccinia 40K promoter, and the lacZ gene, under the control of the C1 promoter, were inserted into the BamHIJ region of the fowlpox virus genome.
- a chromogenic assay for ⁇ -galactosidase was used to identify recombinant viruses containing the lacZ and MART-1 sequences. This method takes advantage of the ability of fowlpox virus to form distinct plaques when grown on monolayers of CED cells. After in vivo recombination, cells were infected with progeny virus until distinct plaques were visible, at which time the plaques were overlaid with a chromogenic substrate for Beta-gaiactosidase (Bluo-gal). Viral plaques expressing lacZ appeared blue against a clear background. Positive plaques were picked from the cell monolayer and their progeny were further propagated.
- Beta-gaiactosidase Beta-gaiactosidase
- the structure of the plasmid transfer vector was verified by restriction endonuclease digestion using Xba I and BamHI.
- the products of digestion with these enzymes were subjected to Southern blot analysis using labeled probes corresponding to the MART-1 gene and to the fowlpox BamHI J sequences.
- the DNA fragments visualized by these methods were of the predicted sizes, and the presence of the MART-1 gene was unequivocally demonstrated, thus confirming the predicted structure of the plasmid.
- the recombinant pox virus set forth below in Table 2 can be constructed using similar techniques.
- IL-2 rV-gp1 00/IL-2 pT4048 gp100 + IL-2 (gpl OO rF-gp100/IL-2 pT2077 gp1 00 + IL-2 above) IL-2:
Abstract
Description
Claims
Priority Applications (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU36706/97A AU718945B2 (en) | 1996-07-25 | 1997-07-09 | Recombinant pox virus for immunization against tumor-associated antigens |
CA002261990A CA2261990A1 (en) | 1996-07-25 | 1997-07-09 | Recombinant pox virus for immunization against tumor-associated antigens |
EP97933544A EP0951559A1 (en) | 1996-07-25 | 1997-07-09 | Recombinant pox virus for immunization against tumor-associated antigens |
JP10508881A JP2000515759A (en) | 1996-07-25 | 1997-07-09 | Recombinant poxvirus for immunization against tumor-associated antigens |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US68628196A | 1996-07-25 | 1996-07-25 | |
US08/686,281 | 1996-07-25 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO1998004728A1 true WO1998004728A1 (en) | 1998-02-05 |
Family
ID=24755677
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US1997/012546 WO1998004728A1 (en) | 1996-07-25 | 1997-07-09 | Recombinant pox virus for immunization against tumor-associated antigens |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP0951559A1 (en) |
JP (1) | JP2000515759A (en) |
AU (1) | AU718945B2 (en) |
CA (1) | CA2261990A1 (en) |
WO (1) | WO1998004728A1 (en) |
Cited By (8)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001030847A1 (en) * | 1999-10-22 | 2001-05-03 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
JP2002526419A (en) * | 1998-10-05 | 2002-08-20 | ファーメクサ エイ/エス | Novel methods for therapeutic vaccination |
EP1589108A2 (en) * | 1997-06-09 | 2005-10-26 | Oxxon Therapeutics Limited | Methods and reagents for vaccination which generate a CD8 T cell immune response |
US7273605B2 (en) | 2001-11-30 | 2007-09-25 | Isis Innovation Limited | Vaccine |
US7786278B2 (en) | 2002-04-09 | 2010-08-31 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
US7851212B2 (en) | 2000-05-10 | 2010-12-14 | Sanofi Pasteur Limited | Immunogenic polypeptides encoded by MAGE minigenes and uses thereof |
US8282935B2 (en) | 2001-07-30 | 2012-10-09 | Isis Innovation Limited | Materials and methods relating to improved vaccination strategies |
US8562970B2 (en) | 2003-10-08 | 2013-10-22 | Sanofi Pasteur Limited | Modified CEA/B7 vector |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996010419A2 (en) * | 1994-10-03 | 1996-04-11 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer | Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |
WO1996011279A2 (en) * | 1994-10-03 | 1996-04-18 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
-
1997
- 1997-07-09 JP JP10508881A patent/JP2000515759A/en active Pending
- 1997-07-09 AU AU36706/97A patent/AU718945B2/en not_active Ceased
- 1997-07-09 WO PCT/US1997/012546 patent/WO1998004728A1/en not_active Application Discontinuation
- 1997-07-09 CA CA002261990A patent/CA2261990A1/en not_active Abandoned
- 1997-07-09 EP EP97933544A patent/EP0951559A1/en not_active Withdrawn
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1996010419A2 (en) * | 1994-10-03 | 1996-04-11 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services, Office Of Technology Transfer | Composition comprising a recombinant virus expressing an antigen and a recombinant virus expressing an immunostimulatory molecule |
WO1996011279A2 (en) * | 1994-10-03 | 1996-04-18 | The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule b7 gene in a recombinant virus expressing system |
Non-Patent Citations (3)
Title |
---|
BAXBY D: "RECOMBINANT POXVIRUS VACCINES", REVIEWS IN MEDICAL MICROBIOLOGY, vol. 4, no. 2, April 1993 (1993-04-01), pages 80 - 88, XP000600230 * |
BRONTE V ET AL: "IL-2 ENHANCES THE FUNCTION OF RECOMBINANT POXVIRUS-BASED VACCINES IN THE TREATMENT OF ESTABLISHED PULMONARY METASTASES", JOURNAL OF IMMUNOLOGY, vol. 154, no. 10, 15 May 1995 (1995-05-15), pages 5282 - 5292, XP002030630 * |
YIFAN ZHAI ET AL: "ANTIGEN-SPECIFIC TUMOR VACCINES DEVELOPMENT AND CHARACTERIZATION OF RECOMBINANT ADENOVIRUSES ENCODING MART1 OR GP100 FOR CANCER THERAPY", JOURNAL OF IMMUNOLOGY, vol. 156, no. 2, 15 January 1996 (1996-01-15), pages 700 - 710, XP000602287 * |
Cited By (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7514087B2 (en) | 1997-06-09 | 2009-04-07 | Oxxon Therapeutics Limited | Methods and reagents for immunization which generate a CD8 T cell immune response |
EP1589108A2 (en) * | 1997-06-09 | 2005-10-26 | Oxxon Therapeutics Limited | Methods and reagents for vaccination which generate a CD8 T cell immune response |
EP1589108A3 (en) * | 1997-06-09 | 2006-03-22 | Oxxon Therapeutics Limited | Methods and reagents for vaccination which generate a CD8 T cell immune response |
US7407661B2 (en) | 1997-06-09 | 2008-08-05 | Oxxon Therapeutics Limited | Methods and reagents that generate a CD8 T cell immune response |
EP2058399A1 (en) * | 1997-06-09 | 2009-05-13 | Oxxon Therapeutics Limited | Methods and reagents for vaccination which generate a CD8 T cell immune response |
JP2002526419A (en) * | 1998-10-05 | 2002-08-20 | ファーメクサ エイ/エス | Novel methods for therapeutic vaccination |
US7820633B2 (en) | 1998-10-05 | 2010-10-26 | Bn Immunotherapeutics, Inc. | Methods for therapeutic vaccination |
WO2001030847A1 (en) * | 1999-10-22 | 2001-05-03 | Aventis Pasteur Limited | Modified gp100 and uses thereof |
US7851212B2 (en) | 2000-05-10 | 2010-12-14 | Sanofi Pasteur Limited | Immunogenic polypeptides encoded by MAGE minigenes and uses thereof |
US8282935B2 (en) | 2001-07-30 | 2012-10-09 | Isis Innovation Limited | Materials and methods relating to improved vaccination strategies |
US7273605B2 (en) | 2001-11-30 | 2007-09-25 | Isis Innovation Limited | Vaccine |
US7786278B2 (en) | 2002-04-09 | 2010-08-31 | Sanofi Pasteur Limited | Modified CEA nucleic acid and expression vectors |
US8562970B2 (en) | 2003-10-08 | 2013-10-22 | Sanofi Pasteur Limited | Modified CEA/B7 vector |
Also Published As
Publication number | Publication date |
---|---|
AU718945B2 (en) | 2000-05-04 |
CA2261990A1 (en) | 1998-02-05 |
JP2000515759A (en) | 2000-11-28 |
EP0951559A1 (en) | 1999-10-27 |
AU3670697A (en) | 1998-02-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US7410644B2 (en) | Recombinant pox virus for immunization against tumor-associated antigens | |
US7118738B2 (en) | Recombinant pox virus for immunization against MUC1 tumor-associated antigen | |
AU774076B2 (en) | A recombinant vector expressing multiple costimulatory molecules and uses thereof | |
US6969609B1 (en) | Recombinant vector expressing multiple costimulatory molecules and uses thereof | |
AU712714B2 (en) | Enhanced immune response by introduction of cytokine gene and/or costimulatory molecule B7 gene in a recombinant virus expressing system | |
AU718945B2 (en) | Recombinant pox virus for immunization against tumor-associated antigens | |
CA2252406A1 (en) | Heterologous boosting immunizations | |
US20050100558A1 (en) | Heterologous boosting immunizations | |
AU767562B2 (en) | Recombinant pox virus for immunization against tumor-associated antigens | |
AU2003266471A1 (en) | Recombinant pox virus for immunization against tumor-associated antigens | |
EP1865065A1 (en) | A recombinant vector expressing multiple costimulatory molecules and uses thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AU CA JP |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): AT BE CH DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
ENP | Entry into the national phase |
Ref document number: 2261990 Country of ref document: CA Ref country code: CA Ref document number: 2261990 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 1997933544 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 1997933544 Country of ref document: EP |
|
WWW | Wipo information: withdrawn in national office |
Ref document number: 1997933544 Country of ref document: EP |